Ganetespib (STA-9090)

Catalog No.S1159

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Cited by 21 Publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 10.1038/nature21064

PubMed: 28178232 ( click the link to review the publication )

Cell, 2017, 168(5):856-866

PubMed: 28215707 ( click the link to review the publication )

Nat Commun, 2019, 10(1):402

PubMed: 30679438 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Endocr Relat Cancer, 2019, 10.1530/ERC-18-0509

PubMed: 30730850 ( click the link to review the publication )

Front Endocrinol (Lausanne), 2019, 10:487

PubMed: 31379752 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.220871

PubMed: 31439673 ( click the link to review the publication )

Transl Lung Cancer Res, 2019, 8(4):340-351

PubMed: 31555510 ( click the link to review the publication )

Mol Cell, 2018, 69(4):594-609

PubMed: 29452639 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Mol Cancer Res, 2018, 10.1158/1541-7786

PubMed: 30002191 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Nat Commun, 2017, 8(1):422

PubMed: 28871086 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1232

PubMed: 28450729 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Hum Mol Genet, 2015, 10.1093/hmg/ddv136

PubMed: 25877301 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1017

PubMed: 25297628 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(5):1015-22

PubMed: 25205430 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Targets

HSP90 ^[1]
(OSA 8 cells)

4 nM

In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. ^[1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. ^[1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. ^[2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. ^[3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.^[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. ^[4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HL60	M1j6[2Fxd3C2b4Ppd{BCe3OjeR?=	MX[zNE85OC9zNUCvNlUxKG6P	MXeyOE81QC95MjDo		NYSwXppJcW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{	Mn3lNlU5QDJ3NUC=
MV411	NUjQcGxOSXCxcITvd4l{KEG\|c3H5	MXGzNE85OC9zNUCvNlUxKG6P	NXLBdJd7OjRxNEivO\|IhcA>?		NWKxdJJ2cW6mdXPld{Bld3OnIHTldIVv\GGwdDDpcoR2[3Srb36gc4Yh[XCxcITvd4l{	NUWz[G82OjV6OEK1OVA>
MGC-803	MnPZR4VtdCCYaXHibYxqfHliQYPzZZk>	NFG4W4QxNjFvMUCwNEBvVQ>?	MWK3NkBp		MXPpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NWS4[3RrOjV3OUC4NFU>
SGC-7901	MlzTR4VtdCCYaXHibYxqfHliQYPzZZk>	MXSwMlEuOTByMDDuUS=>	M3PBeVczKGh?		MlnWbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MorRNlU2QTB6MEW=
MKN-28	M2fa[GNmdGxiVnnhZoltcXS7IFHzd4F6	M4TX[lAvOS1zMECwJI5O	NEfuNpA4OiCq		M{TncYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MWGyOVU6ODhyNR?=
MGC-803	MoniSpVv[3Srb36gRZN{[Xl?	NGDHb5YxNjFvMUCwNEBvVQ>?	MoLyNlQhcA>?		MUnpcoR2[2W\|IFeyM20h[2WubD3jfYNt\SCjcoLld5Q>	MWGyOVU6ODhyNR?=
HCT-116	Mly2SpVv[3Srb36gRZN{[Xl?	NInjbZM2OG6P	M{fv[VI1KGh?	NVzUNo1mTE2VTx?=	MYHpcoR2[2WmIFewM2cyKGG{cnXzeC=>	NGnrO\|QzPTJzMEe5OC=>
HT-29	NHTYOI9HfW6ldHnvckBCe3OjeR?=	MlPIOVBvVQ>?	MnHONlQhcA>?	NEPG[VhFVVOR	M4G5N4lv\HWlZXSgS\|AwTzFiYYLy[ZN1	NEm0NFEzPTJzMEe5OC=>
SCC25	Ml\tR5l1d3irY3n0fUBCe3OjeR?=	M3f5fVExNzVyIH7N	MUCyOEBp		NHHjWmll\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3Wg[IVx\W6mZX70cJk>	MYGyOVIxPTR\|MB?=
FUDA	NF;tVmxEgXSxeHnjbZR6KEG\|c3H5	MlvTNVAwPTBibl2=	NUC1fVBHOjRiaB?=		MX7k[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm=	NEXNTVMzPTJyNUSzNC=>
Detroit562	NWHGUJNiS3m2b4jpZ4l1gSCDc4PhfS=>	MkHrNVAwPTBibl2=	M2nmSFI1KGh?		M37nc4Rm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	NX\F[IJvOjV{MEW0N\|A>
CAL27	M3;FcGN6fG:6aXPpeJkhSXO\|YYm=	NV;kRY9VOTBxNUCgcm0>	MXeyOEBp		MUXk[YNz\WG\|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm=	NUWyRlBkOjV{MEW0N\|A>
DSH1	NGH5TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTZibl2=	M2rDb\|I1Pzh2OEO5
SW-1710	NFH1VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTNPVFKSzVyPU[gcm0>	MXeyOFc5PDh\|OR?=
T24	NUnmOIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGqySmpKSzVyPUegcm0>	NGjYXYozPDd6NEizPS=>
RT112	NHXVbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTlibl2=	NWjhUHl6OjR5OES4N\|k>
639-V	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M325RWlEPTB;MUCgcm0>	MV2yOFc5PDh\|OR?=
SCaBER	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWm5N\|ZwUUN3ME2xNEBvVQ>?	NWTHXXNmOjR5OES4N\|k>
BFTC	NXjiU\|k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYe0R4VHUUN3ME2xO{BvVQ>?	NXXvboVKOjR5OES4N\|k>
J82	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7Sb5hnUUN3ME2xPEBvVQ>?	M1nrXVI1Pzh2OEO5
HT-1376	NHixZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1K4[GlEPTB;MkGgcm0>	NULQUWV[OjR5OES4N\|k>
647-V	NHLHcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW5OmxpUUN3ME2yO{BvVQ>?	NGnVcpYzPDd6NEizPS=>
UM-UC3	M1LXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nqXmlEPTB;M{Ogcm0>	Mn7QNlQ4QDR6M{m=
LB831-BLC	M1jNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLyTWM2OD1\|NDDuUS=>	M1jX[lI1Pzh2OEO5
KU-19-19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTN4IH7N	NYPnRXBmOjR5OES4N\|k>
35612	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;NTWM2OD1\|ODDuUS=>	NIDlSoozPDd6NEizPS=>
5637	NXXqZVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTR2IH7N	NYLSRm5LOjR5OES4N\|k>
HT-1197	NV;EPHdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTV\|IH7N	NV[wSnBSOjR5OES4N\|k>
MGH-U3	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELuN4RKSzVyPUWzJI5O	MojTNlQ4QDR6M{m=
TCCSUP	NUP6N25kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fyR2lEPTB;MUSyJI5O	MUGyOFc5PDh\|OR?=
RT4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFG2WGhKSzVyPUG3N\|Mhdk1?	NH\5RlYzPDd6NEizPS=>
SW780	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjuNJR4UUN3ME2zOFUyKG6P	NYrDSZpoOjR5OES4N\|k>
RKO	MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nuXWlEPTB;NDDuUS=>	NV[0fHZTOjR4OEK3OFc>
LS-411 N	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXNV4xKSzVyPUWgcm0>	NFTaSI4zPDZ6Mke0Oy=>
SW620	M{f6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmX0TWM2OD16IH7N	NXvEcWxHOjR4OEK3OFc>
HCT-15	NF60W4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrUd4hPUUN3ME24JI5O	NIq5[24zPDZ6Mke0Oy=>
HuTu-80	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTF\|IH7N	NXvwT3RLOjR4OEK3OFc>
HCT 116	M2jpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\ZOG1KSzVyPUG0JI5O	MX[yOFY5Ojd2Nx?=
COLO-205	NFXCSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTF2IH7N	MmH3NlQ3QDJ5NEe=
NCI-H747	NXnGU5JmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXITWM2OD1zNzDuUS=>	M{PqPFI1Pjh{N{S3
COLO-678	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJzIH7N	MoHQNlQ3QDJ5NEe=
LoVo	MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPZN213UUN3ME2yNkBvVQ>?	NWXpSlR4OjR4OEK3OFc>
LS-1034	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf6WYFCUUN3ME2zNUBvVQ>?	M{X2VVI1Pjh{N{S3
SNU-C2B	M1qzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTR3IH7N	Ml\wNlQ3QDJ5NEe=
LS-123	NEH1WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFS4boxKSzVyPUezJI5O	NUC4clc1OjR4OEK3OFc>
SK-CO-1	M1XnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknUTWM2OD16MTDuUS=>	NF\3T\|kzPDZ6Mke0Oy=>
HCC2998	M1:1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGT6bm5KSzVyPUGyPEBvVQ>?	MXyyOFY5Ojd2Nx?=
MDA-MB-231	Mnm4SpVv[3Srb36gRZN{[Xl?	Mn7qNVAxKG6P	M1rJZ\|MxKG2rbh?=		NVvmWmlVcW6qaXLpeJMh[WOldX31cIF1cW:wIH;mJGhKTi1zzsG=	NUD4T4VtOjR{NEiyOlU>
MDA-MB-435	NGrkfWFHfW6ldHnvckBCe3OjeR?=	MVKxNFAhdk1?	NXHGWpJ4OzBibXnu		MWfpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>?	MXGyOFI1QDJ4NR?=
BT-20	NGW1bFdHfW6ldHnvckBCe3OjeR?=	NFzQd4gyODBxMkWwJI5O	M3;xflI1KGh?		MYXy[ZN2dHSnZDDpckBiKGSxc3Wt[IVx\W6mZX70JIRme3SjYnnsbZpifGmxbjDv[kBGT0[ULDDJS2YuUVJuIF3FWEwh[W6mIFPSRWY>	MV[yOFE4OzV2MR?=
MDA-MB-231	MXXGeY5kfGmxbjDBd5NigQ>?	MWSxNFAhdk1?	NX3UO2RZOjRiaB?=		MknDbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCjbnSgbY53[XOrdnWgZ4Fx[WOrdIpCpC=>	NUPURpJ[OjRzN{O1OFE>
H82	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUD1eIlSUUN3ME2zNE4zPyCwTR?=	M2H5W\|I1OTZ4NUC1
GLC4	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTJyLkS3JI5O	M{HlfVI1OTZ4NUC1
H69	NEfqfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDHc3BKSzVyPUizMlM3KG6P	NVTR[4F5OjRzNk[1NFU>
H128	NVTqS3ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEKydYRKSzVyPU[5MlU2KG6P	NH\QVpkzPDF4NkWwOS=>
H146	NHLTSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDrd3lKSzVyPUK4MlUyKG6P	NFnVVpEzPDF4NkWwOS=>
H187	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrHfpRKSzVyPUK0Mlk6KG6P	MVmyOFE3PjVyNR?=
H526	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFH0SpFKSzVyPUKxMlY1KG6P	M{C1U\|I1OTZ4NUC1
N592	NGfwcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLTTWM2OD1zND6xNkBvVQ>?	NXjFb4NkOjRzNk[1NFU>
H620	M3XPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jrPWlEPTB;M{KuOlchdk1?	NYjaWG9KOjRzNk[1NFU>
H792	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDTTWM2OD12NT6wO{BvVQ>?	MlTPNlQyPjZ3MEW=
H1173	NUXzVHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnYV5FuUUN3ME2xNk43OiCwTR?=	NF7VXXkzPDF4NkWwOS=>
AC3	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjWTWM2OD1{NT65JI5O	M1Pq[lI1OTZ4NUC1
H82	NW\FNYlqTnWwY4Tpc44hSXO\|YYm=	M3:0Z\|MxKG6P	MWS3NkBp		M17nSYlv\HWlZYOgdIVze2m\|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=>	M4j5b\|I1OTZ4NUC1
GLC4	NEnNRnpHfW6ldHnvckBCe3OjeR?=	NVzudY5jOzBibl2=	MnHpO\|IhcA>?		MUPpcoR2[2W\|IIDldpNqe3SnboSgS\|IwVSCyaHHz[UBienKnc4S=	M1uxZlI1OTZ4NUC1
H146	Mom3SpVv[3Srb36gRZN{[Xl?	MVqzNEBvVQ>?	NFTq[pU4OiCq		MX7pcoR2[2W\|IIDldpNqe3SnboSgS\|IwVSCyaHHz[UBienKnc4S=	M13pO\|I1OTZ4NUC1
OVCAR-5	MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MXGwMVExODBibl2=	NHLOdWo4OiCq		MnrMbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MoXXNlM6ODBzM{[=
OVCAR-8	NGK1VZdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NV3FTVlQOC1zMECwJI5O	MXu3NkBp		Mn21bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MoTYNlM6ODBzM{[=
A1847	NYnLTHVsS2WubDDWbYFjcWyrdImgRZN{[Xl?	NYDDeolJOC1zMECwJI5O	M4\xNVczKGh?		MVrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MkHaNlM6ODBzM{[=
SKOV-3	NFzieG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHTHUW0xNTFyMECgcm0>	MUC3NkBp		NED0TGdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	NH7wTnUzOzlyMEGzOi=>
OVCAR-5	MVnBdI9xfG:\|aYOgRZN{[Xl?	MmGwNVAuOTByIH7N	NEm2W\|gzPC92OD:3NkBp		NYCwV5MxcW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboTsfS=>	Mn7nNlM6ODBzM{[=
OVCAR-8	M3zLU2Fxd3C2b4Ppd{BCe3OjeR?=	NF\YbVAyOC1zMECgcm0>	M176SVI1NzR6L{eyJIg>		NVzn[GM{cW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboTsfS=>	MkjZNlM6ODBzM{[=
A1847	NXXzfXM4SXCxcITvd4l{KEG\|c3H5	NWHoZmdrOTBvMUCwJI5O	MYWyOE81QC95MjDo		NVixOYZicW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboTsfS=>	M330VFI{QTByMUO2
H2228	MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGrXdIUxNTFyMECgcm0>	MmXvO\|IhcA>?		NYSweXd6UUN3ME2xN{BvVQ>?	M{LGNlI{PTN\|Mk[1
H3122	NIXK[llE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFLRUHcxNTFyMECgcm0>	M4DxfVczKGh?		MlL1TWM2OD1zMDDuUS=>	NES2SGEzOzV\|M{K2OS=>
K008	M2DPRmNmdGxiVnnhZoltcXS7IFHzd4F6				Ml7ITWM2OD14MDDuUS=>	NUPyfJJSOjN2MUi1NlM>
K028	MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				M4D2VGlEPTB;OESgcm0>	NIricFUzOzRzOEWyNy=>
K029	MoqwR4VtdCCYaXHibYxqfHliQYPzZZk>				NX\kfnNSUUN3ME20OkBvVQ>?	NXnnSHQ5OjN2MUi1NlM>
M23	MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=>				NW\EZpN{UUN3ME2zO{42KG6P	NYXLcIp[OjN2MUi1NlM>
K033	NX\oWXNTS2WubDDWbYFjcWyrdImgRZN{[Xl?				NEXYeINKSzVyPUe1MlUhdk1?	MX[yN\|QyQDV{Mx?=
K008	Mn\HSpVv[3Srb36gRZN{[Xl?	NFm2UHQzPTBibl2=	MVuyOEBp		MX7pcoR2[2W\|IFeyJIFzemW\|dB?=	NIrQZoUzOzRzOEWyNy=>
K028	M1G3eWZ2dmO2aX;uJGF{e2G7	MmjLNlUxKG6P	M1O4TFI1KGh?		MYnpcoR2[2W\|IFeyJIFzemW\|dB?=	M4rWWlI{PDF6NUKz
K029	M1e2VWZ2dmO2aX;uJGF{e2G7	M4\5UFI2OCCwTR?=	NUe5WHd6OjRiaB?=		MXPpcoR2[2W\|IFexJIFzemW\|dB?=	Ml3sNlM1OTh3MkO=
M23	NXLsUG5KTnWwY4Tpc44hSXO\|YYm=	Ml75NlUxKG6P	NHjNRmUzPCCq		NXfDNohScW6mdXPld{BIOSCjbnSgS\|IwVSCjcoLld5Q>	M1HzTVI{PDF6NUKz
K033	M4npNWZ2dmO2aX;uJGF{e2G7	MVOyOVAhdk1?	NEPvdXczPCCq		MW\pcoR2[2W\|IHGgcY9l\XO2IHnuZ5Jm[XOnIHnuJGcyKHCxcIXsZZRqd25?	M{nzW\|I{PDF6NUKz
K008	NFn2PYZCeG:ydH;zbZMhSXO\|YYm=	M4DKZVExOCCwTR?=	M3fPTFczKGh?		Mn25d4lodmmoaXPhcpRtgSCrbnT1Z4V{KGGyb4D0c5Nqew>?	MVyyN\|QyQDV{Mx?=
K028	M1\lNGFxd3C2b4Ppd{BCe3OjeR?=	M3OzVVExOCCwTR?=	M1L0UlczKGh?		MWDzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{	MYGyN\|QyQDV{Mx?=
K029	NID6fFZCeG:ydH;zbZMhSXO\|YYm=	Moi3NVAxKG6P	NVXYT3l{PzJiaB?=		NFPnXnp{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m\|	M1PUUVI{PDF6NUKz
M23	NEfwXHVCeG:ydH;zbZMhSXO\|YYm=	M1L4SFExOCCwTR?=	NVPoSZdoPzJiaB?=		NYiy[FVDe2mpbnnmbYNidnSueTDpcoR2[2W\|IHHwc5B1d3Orcx?=	MXSyN\|QyQDV{Mx?=
K033	MojGRZBweHSxc3nzJGF{e2G7	NYPNOVVFOTByIH7N	MVK3NkBp		MYjzbYdvcW[rY3HueIx6KGmwZIXj[ZMh[XCxcITvd4l{	NXPVOYR1OjN2MUi1NlM>
RD	MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LKfmlEPTB;ODDuUS=>	NETTVXczOzNyM{e0NS=>
Rh41	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnznTWM2OD1zMD60JI5O	MX[yN\|MxOzd2MR?=
Rh18	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF60U5FKSzVyPU[uNkBvVQ>?	M4DYTFI{OzB\|N{Sx
Rh30	M3HGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF32dndKSzVyPUWuOkBvVQ>?	NULtO4ljOjN\|MEO3OFE>
BT-12	M3e1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrWWnB3UUN3ME2xOE4{KG6P	MXeyN\|MxOzd2MR?=
CHLA-266	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jLRWlEPTB;MkeuNUBvVQ>?	M17NcFI{OzB\|N{Sx
TC-71	NGDIeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHWxUWVKSzVyPUSuOUBvVQ>?	NIHw[4YzOzNyM{e0NS=>
CHLA-9	MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HoWWlEPTB;ND62JI5O	MUGyN\|MxOzd2MR?=
CHLA-10	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTVwNzDuUS=>	NWHRNmV{OjN\|MEO3OFE>
CHLA-258	M{DPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTZwNDDuUS=>	NV7zWZloOjN\|MEO3OFE>
SJ-GBM2	NVq4UI9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vYbGlEPTB;MUKuPUBvVQ>?	NYH3bplyOjN\|MEO3OFE>
NB-1643	NYXZOXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Xo[2lEPTB;Nz60JI5O	NXXxcFYyOjN\|MEO3OFE>
NB-EBc1	M3P1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTF4Lkigcm0>	M33TeFI{OzB\|N{Sx
CHLA-90	NXraOnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2[yNWlEPTB;MkKuN{BvVQ>?	MlnHNlM{ODN5NEG=
CHLA-136	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXn5TXIyUUN3ME2yN{4zKG6P	M3rlZVI{OzB\|N{Sx
NALM-6	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTFzLkegcm0>	NVHn[5VsOjN\|MEO3OFE>
COG-LL-317	M2X3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLBVm1xUUN3ME20MlQhdk1?	NFzZWngzOzNyM{e0NS=>
RS4;11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfWcY9lUUN3ME2xN{42KG6P	NGDMfIkzOzNyM{e0NS=>
MOLT-4	NID1OnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLGUGhKSzVyPUGwMlYhdk1?	NHOwT4YzOzNyM{e0NS=>
CCRF-CEM (1)	M4qwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1z4NWlEPTB;MUKuOUBvVQ>?	MXyyN\|MxOzd2MR?=
CCRF-CEM (2)	NF\INWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj4TWM2OD15LkKgcm0>	M3;jWVI{OzB\|N{Sx
Kasumi-1	NVPlOFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVyyfpU{UUN3ME21Mlghdk1?	MUOyN\|MxOzd2MR?=
Karpas-299	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG4cXRKSzVyPUmuOkBvVQ>?	NUe0NHZoOjN\|MEO3OFE>
Ramos-RA1	NVfDTY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTdwNDDuUS=>	M4m1XVI{OzB\|N{Sx
LNCaP	M4PHZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUS5b3hFUUN3ME24JI5O	NYLJbHVLOjNzNUKwNFQ>
VCaP	M1PXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTPd2FTUUN3ME23JI5O	M1O1flI{OTV{MEC0
H1355	NXfBO45XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTVibl2=	NFWzOngzOzBzMkK0PC=>
H157	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHqcGhKSzVyPUegcm0>	MUeyN\|AyOjJ2OB?=
H460	NW[wb\|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPMWZJSUUN3ME24JI5O	MVKyN\|AyOjJ2OB?=
IA-LM	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofYTWM2OD1zMDDuUS=>	NGLHSmozOzBzMkK0PC=>
HOP-62	MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHzTWM2OD1zMTDuUS=>	Mn7tNlMxOTJ{NEi=
H23	M1zKZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnpTWM2OD1zMTDuUS=>	NWTIUZI{OjNyMUKyOFg>
H2030	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf3Tld1UUN3ME2xNkBvVQ>?	MU[yN\|AyOjJ2OB?=
H441	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDL[I1xUUN3ME2xOEBvVQ>?	MkC3NlMxOTJ{NEi=
H2212	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTGTWM2OD1zNzDuUS=>	MlXYNlMxOTJ{NEi=
SK-LU-1	M{WyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF6IH7N	M2LTc\|I{ODF{MkS4
H2009	NXrxW\|RnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTDTWM2OD1zOTDuUS=>	MUGyN\|AyOjJ2OB?=
H1792	NXO0[\|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fUbmlEPTB;MkCgcm0>	M3mwblI{ODF{MkS4
COR-L23	NXH4[4JnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn1TWM2OD1{MjDuUS=>	NH2yU2kzOzBzMkK0PC=>
H727	M3zWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDwcm1KSzVyPUK4JI5O	MnHENlMxOTJ{NEi=
H1734	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTJ6IH7N	MXeyN\|AyOjJ2OB?=
H358	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjvVnVKSzVyPUK5JI5O	NWrCW5pzOjNyMUKyOFg>
A549	M{XV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3sUHJ6UUN3ME20N{BvVQ>?	MWeyN\|AyOjJ2OB?=
H2122	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTx[ph7UUN3ME21N{BvVQ>?	M3;Kc\|I{ODF{MkS4
Calu-1	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXETWM2OD13ODDuUS=>	NVX1Zos2OjNyMUKyOFg>
Calu-6	M2P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlniTWM2OD14NDDuUS=>	NGfXUXIzOzBzMkK0PC=>
NCI-H1975	M2K1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVO0PEBp		M4S5S2lEPTB;MU[gcm0>	M4jDO\|IzOTR2Nk[1
NCI-H1975	NXTvWZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH[zSIY4OiCq		Ml;wTWM2OD16IH7N	M4flWlIzOTR2Nk[1

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK; PubMed: 23418523 PLoS One Downregulation of multiple signaling pathways by ganetespib in melanoma cells.A. Cells were treated with indicated amounts of ganetespib for 24 h. B-RAF and N-RAS mutational status of each cell line is indicated. p27(Kip1) / p21 (Cip1) / Cyclin D1 / Cyclin E / Cyclin B1 / CDK1 / CDK2 / CDK4; PubMed: 23418523 PLoS One Alterations in expression of multiple cell cycle regulating proteins induced by ganetespib. Cells were treated with indicated amounts of ganetespib for 48 h and analyzed by Western blot analysis. Relative expression levels of proteins (treated vs. control䲧疝Ỵ疞㧀疜膉痘  Survivin / Bcl-2 / Bcl-xl / Mcl-1; PubMed: 23418523 PLoS One Effect of ganetespib on the expression of antiapoptotic proteins. Cells were treated with ganetespib for 48 h and analyzed using Western blot analysis. Relative expression levels of proteins are indicated. B-RAF / C-RAF / N-RAS ; PubMed: 23418523 PLoS One Effect of ganetespib on B-RAF, C-RAF and N-RAS expression in melanoma cells.Cells were treated with indicated amounts of ganetespib for 48 h and subjected to Western blot analysis. HER2 / p-STAT3 / BIM ; PubMed: 25077897 Target Oncol NCI-H1975 cells were incubated with the indicated concentrations of ganetespib for 24 h. Cell lysates were analyzed by Western blotting. CDK1 / Cyclin D1 / Cyclin B1 / p27; PubMed: 29717218 Sci Rep Cropped Western blot images of the indicated cell cycle regulators are shown in ganetespib-treated (0–300 nM for 16 hours) BT474 and SKBR3 cells. c-PARP / c-caspase 3 / caspase 8 / c-caspase 8 / caspase 9 / c-caspase 9; PubMed: 29717218 Sci Rep Cropped images of Western blots at the target molecular weights for the indicated apoptotic markers are shown in ganetespib-treated (0, 10, 30, 100, 300 nM for 16 hours) BT474 and SKBR3 cells. ErbB2 / pErbB2 / Src / pSrc / mTOR / pmTOR / Bad / pBad / GSK3 / pGSK3; PubMed: 29717218 Sci Rep Ganetespib inhibits RTK signaling in ErbB2+ breast cancer cells. BT474 and SKBR3 cells were treated with ganetespib (0, 10, 30, 100, or 300 nM) for 16 hours, followed by Western blot analysis (cropped images) of the expression and activation/phosphorylati䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖 Wee1 / p-Wee1 / Chk1 / p-Chk1; PubMed: 27834954 Cell Death Differ Hsp90 inhibition degrades the G2/M checkpoint kinases Wee1 and Chk1. The cells were treated with 200 nM ganetespib and 75 μM carboplatin for 24 h followed by immunoblot analysis. Carboplatin treatment leads to the activation of Chk1, indicated by phospho—䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ	23418523 25077897 29717218 27834954
Growth inhibition assay	Cell viability ; PubMed: 23418523 PLoS One A. Ganetespib reduced viability. Cells were treated with varying amounts of ganetespib for 72 h and subjected to MTS assay. Data are expressed as mean±SD of three independent experiments. B. Mutational status and ganetespib IC50 of cell lines.	23418523

In vivo

Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.^[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.^[4]

Protocol

Cell Research:^[1]	- Collapse Cell lines: OSA cells Concentrations: 0.001-1μM Incubation Time: 5 days Method: A total of 1.5 × 10³ OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100. (Only for Reference)
Animal Research:^[4]	- Collapse Animal Models: Female severe combined immune-deficient (SCID) mice Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40 Dosages: 25 mg/kg/day for 3 days Administration: Tail vein injection (Only for Reference)

Cell Research:^[1]

- Collapse

Cell lines: OSA cells
Concentrations: 0.001-1μM
Incubation Time: 5 days
Method: A total of 1.5 × 10³ OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female severe combined immune-deficient (SCID) mice
Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
Dosages: 25 mg/kg/day for 3 days
Administration: Tail vein injection
(Only for Reference)

References

[4] Lin TY, et al. Exp Hematol. 2008, 36(10), 1266-1277.

- Collapse

Solubility (25°C)

In vitro	DMSO	40 mg/mL (109.76 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ganetespib (STA-9090) SDF

Molecular Weight	364.4
Formula	C₂₀H₂₀N₄O₃
CAS No.	888216-25-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02192541	Terminated	Drug: Ziv-Aflibercept\|Drug: Ganetespib	Neoplasms	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	December 2 2014	Phase 1
NCT02008877	Completed	Drug: ganetespib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors (MPNST)\|Sarcoma	Sarcoma Alliance for Research through Collaboration\|Synta Pharmaceuticals Corp.\|United States Department of Defense	December 2013	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does this inhibitor inhibit both isoforms of HSP90?
Answer:
We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-AAG (Tanespimycin) : Phase III for Gastrointestinal Stromal Tumors.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Ganetespib (STA-9090)

Cited by 21 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ganetespib (STA-9090) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ganetespib (STA-9090)

Cited by 21 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ganetespib (STA-9090) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)